Greenwich LifeSciences (GLSI)

Executive Summary

Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have undergone surgery. The company's lead candidate, GLSI-100 (GP2 + GM-CSF), is currently in a Phase 3 clinical trial (NCT05232916) for HER2/neu-positive breast cancer. The trial is recruiting and expected to complete in December 2026. Greenwich LifeSciences focuses on addressing a significant unmet need in breast cancer recurrence prevention, leveraging a novel peptide-based vaccine approach. As a public company with a single pipeline asset, its valuation is highly dependent on trial outcomes. While the Phase 3 trial represents a major milestone, the company faces typical clinical development risks including enrollment challenges, efficacy endpoints, and regulatory hurdles. Investors should monitor trial progress and potential interim data releases.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Trial Completion and Data Readout30% success
• Q3 2026Interim Analysis or DSMB Update25% success
• TBDEnrollment Milestone Announcement70% success